Semaglutide and tirzepatide are the two most widely prescribed medications for GLP-1 weight loss treatment today, and they're often the first decision point for anyone starting the process. Both are effective, both are backed by large clinical trials, and both are offered by most major telehealth providers — but they aren't interchangeable. Here's how they actually compare.
Semaglutide is the active ingredient in Wegovy (FDA-approved for weight management) and Ozempic (approved for type 2 diabetes). Tirzepatide is the active ingredient in Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes). Both are also available in compounded form through telehealth providers such as PureForm Health and ThriveWell Rx.
Both medications belong to the broader family of incretin-based therapies, which have rapidly become the standard of care for medical weight management. Despite the similarities in how they're delivered and monitored, the underlying chemistry — and the resulting clinical trial outcomes — differ enough that the choice between them is worth understanding rather than treating as a coin flip.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single pathway) | Dual GLP-1 / GIP receptor agonist |
| Brand name (weight loss) | Wegovy® | Zepbound® |
| Avg. weight loss in trials | ~15% of body weight | ~20-22% of body weight |
| Trial duration | 68 weeks (STEP 1) | 72 weeks (SURMOUNT-1) |
| Dosing frequency | Once weekly injection | Once weekly injection |
| Common side effects | Nausea, constipation, diarrhea | Nausea, constipation, diarrhea (similar profile) |
| FDA approval status | Approved for chronic weight management | Approved for chronic weight management |
Semaglutide activates GLP-1 receptors only. Tirzepatide is a "dual agonist" — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone involved in insulin secretion and fat metabolism, and the theory behind tirzepatide's design is that hitting two pathways at once produces a stronger effect on appetite and metabolism than hitting one alone. Clinical trial data has generally supported that theory, with tirzepatide producing larger average weight loss than semaglutide across comparable trial populations.
That doesn't mean tirzepatide is automatically the better choice for every individual — head-to-head response varies, and some people tolerate or respond to one medication noticeably better than the other. Some clinicians also point out that a single-pathway medication like semaglutide has a longer real-world track record, since it and its diabetes counterpart have been prescribed for a longer period of time, giving providers a deeper base of practical experience to draw from when managing patients.
In the STEP 1 trial, participants taking semaglutide lost an average of approximately 15% of their body weight over 68 weeks. In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide lost an average of about 20-22% of their body weight over 72 weeks. Both trials paired medication with lifestyle counseling, which is standard practice and part of why results were as strong as they were.
It's worth noting these are trial averages, not guarantees — individual results depend on starting weight, dose, adherence, and lifestyle factors. It's also worth noting that both trials used a similar structure: a gradual dose-escalation period followed by an extended maintenance phase, with regular counseling on nutrition and activity throughout. That consistency in trial design is part of why the two data sets are considered reasonably comparable, even though they were conducted as separate studies rather than a true head-to-head trial.
"Tirzepatide tends to produce larger average results in trials, but the right medication is the one you can tolerate and stay consistent with long-term." — WeightBloomX Editorial Team
Both medications share a similar side effect profile dominated by gastrointestinal symptoms — nausea, constipation, diarrhea, and reduced appetite, especially during the first few weeks or after a dose increase. Some patients report that tirzepatide's dual mechanism makes side effects feel somewhat different in character, though this varies by individual and isn't consistent across the population. Both medications carry the same general precautions around personal or family history of certain thyroid conditions and pancreatitis, which a licensed provider will screen for during intake.
Neither medication is inherently "harsher" than the other in a way that applies universally — plenty of patients tolerate tirzepatide with minimal issue, and plenty find semaglutide easier on their system. The most reliable predictor of tolerability tends to be how closely the dose-titration schedule is followed, rather than which of the two medications is chosen. Providers who move slowly through dose increases, and who are responsive when a patient reports discomfort, generally see better outcomes regardless of which medication is prescribed.
A few practical factors tend to drive the decision:
Providers like NovaSlim Rx and VitalShape MD typically offer both options and can adjust your treatment plan if your first choice isn't working well for you. It's also worth asking whether switching between the two later on is straightforward if your needs change — a provider who supports that flexibility gives you more room to find the right fit without starting the entire process over from scratch.
Semaglutide and tirzepatide are both highly effective GLP-1 medications with strong clinical backing. Tirzepatide has shown larger average weight loss in trials thanks to its dual-hormone mechanism, but semaglutide remains a well-studied, effective, and often more widely available option. The best choice comes down to your goals, tolerability, and a conversation with a licensed provider.
This article is for informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any GLP-1 medication.